ReNeuron Group plc
RENE.L · LSE
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 31.5% | 56.8% | -95.8% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | -£0 | -£0 |
| % Margin | 49.6% | 19.6% | -3,597.7% | -169.3% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,342.5% | -2,786.1% | -5,024.9% | -237.6% |
| Other Income/Exp. Net | £0 | £0 | -£0 | £0 |
| Pre-Tax Income | -£0 | -£0 | -£0 | -£0 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,020.4% | -2,404.2% | -4,415.2% | -188.2% |
| EPS | -0.095 | -0.17 | -0.29 | -0.35 |
| % Growth | 44.3% | 41.4% | 17.1% | – |
| EPS Diluted | -0.095 | -0.17 | -0.29 | -0.35 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,201.9% | -2,657.3% | -5,057.6% | -221% |